NEW ZEALAND GAZETTE, No. 25 — 9 MARCH 2017

Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.

Unless specific reference is made otherwise, every reference applies also to medicines that are:

a. preparations and admixtures containing any proportion of any substance listed in the notice.

b. salts and esters of any substance listed in the notice.

c. preparations or extracts of biological materials listed in the notice.

d. salts or oxides of elements listed in the notice.

Unless specific reference is made otherwise, every reference to a medicine applies:

i. if the medicine is in an injection or eye preparation, to any concentration of that medicine; and

ii. if the medicine is not in an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.

Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.

Schedule 1

Prescription Medicines

Alirocumab

Armodafinil

Asfotase alfa

Atezolizumab

Betaine; for the treatment of homocystinuria

Bifonazole; except when specified elsewhere in this Schedule

Desogestrel; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme on oral contraception when sold in the Medsafe approved manufacturer’s original pack containing not more than six months’ supply by a registered pharmacist who has successfully completed the approved training programme

Di-iodohydroxyquinoline

Ethinyloestradiol; except when supplied at a strength of 35 micrograms or less in combination with either levonorgestrel or norethisterone for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme on oral contraception when sold in the Medsafe approved manufacturer’s original pack containing not more than six months’ supply by a registered pharmacist who has successfully completed the approved training programme

Flubromazolam

Follitropin delta

Hexyl aminolevulinate

Ixekizumab

Levonorgestrel; except when specified elsewhere in this Schedule; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme on oral contraception when sold in the Medsafe approved manufacturer’s original pack containing not more than six months’ supply by a registered pharmacist who has successfully completed the approved training programme

Norethisterone; except when supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and the Pharmaceutical Society of New Zealand approved training programme on oral contraception when sold in the Medsafe approved manufacturer’s original pack containing not more than six months’ supply by a registered pharmacist who has successfully completed the approved training programme

Ocrelizumab

Osimertinib

Phleum pratense extract

67